REGENXBIO Inc. - Common Stock (RGNX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2015 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
RGNX on Nasdaq
Shares outstanding
50,868,756
Price per share
$14.59
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
41,025,336
Total reported value
$590,682,386
% of total 13F portfolios
0%
Share change
-627,822
Value change
-$5,458,714
Number of holders
172
Price from insider filings
$14.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENXBIO Inc. - Common Stock (RGNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% $43,942,300 5,062,477 Redmile Group, LLC 30 Jun 2025
JPMORGAN CHASE & CO 7.4% $34,806,291 3,698,862 JPMORGAN CHASE & CO. 31 Dec 2024
BlackRock, Inc. 7.3% -34% $34,616,925 -$16,819,095 3,678,738 -33% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 6% $28,097,808 2,985,952 The Vanguard Group 31 Dec 2024
STATE STREET CORP 4.4% $20,568,858 2,185,851 STATE STREET CORPORATION 31 Dec 2024
BlackRock Portfolio Management LLC 4.1% -35% $30,032,914 -$15,091,042 2,085,619 -33% BlackRock Portfolio Management LLC 31 Dec 2025

As of 31 Dec 2025, 172 institutional investors reported holding 41,025,336 shares of REGENXBIO Inc. - Common Stock (RGNX). This represents 81% of the company’s total 50,868,756 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of REGENXBIO Inc. - Common Stock (RGNX) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 5,756,811 -9.6% 0% $82,898,078
Redmile Group, LLC 8.6% 4,368,804 -6.9% 4.6% $62,910,778
JPMORGAN CHASE & CO 7% 3,553,502 -12% 0% $51,170,429
VANGUARD GROUP INC 6.6% 3,374,140 +1.1% 0% $48,587,616
STATE STREET CORP 4.5% 2,286,736 +15% 0% $32,928,998
MORGAN STANLEY 4% 2,014,787 +18% 0% $29,012,933
GOLDMAN SACHS GROUP INC 3.5% 1,785,437 -3.6% 0% $25,710,293
AQR CAPITAL MANAGEMENT LLC 2.7% 1,361,962 +5.6% 0.01% $19,612,253
Integral Health Asset Management, LLC 2.4% 1,200,000 +9.1% 0.88% $17,280,000
Assenagon Asset Management S.A. 2.3% 1,160,380 +64% 0.03% $16,709,472
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,145,206 +1.7% 0% $16,495,225
22NW, LP 1.8% 923,679 0% 10% $13,300,978
DIMENSIONAL FUND ADVISORS LP 1.8% 903,851 -18% 0% $13,014,235
Nuveen, LLC 1.3% 658,510 +19% 0% $9,482,544
Pale Fire Capital SE 0.98% 499,526 +95% 0.93% $7,193,174
Qube Research & Technologies Ltd 0.87% 442,690 +55% 0.01% $6,374,736
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.77% 391,461 -0.13% 0% $5,637,038
ACADIAN ASSET MANAGEMENT LLC 0.74% 375,399 -5.9% 0.01% $5,404,000
NORTHERN TRUST CORP 0.73% 373,689 -6.8% 0% $5,381,121
STIFEL FINANCIAL CORP 0.66% 335,046 +4.6% 0% $4,824,676
RENAISSANCE TECHNOLOGIES LLC 0.65% 333,086 +7.6% 0.01% $4,796,438
BANK OF AMERICA CORP /DE/ 0.59% 300,609 -28% 0% $4,328,769
HRT FINANCIAL LP 0.59% 299,915 +74% 0.01% $4,318,000
Voss Capital, LP 0.58% 295,000 -41% 0.23% $4,248,000
GSK plc 0.53% 271,456 0% 0.49% $3,908,966

Institutional Holders of REGENXBIO Inc. - Common Stock (RGNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 41,025,336 $590,682,386 -$5,458,714 $14.40 172
2025 Q3 41,385,428 $399,433,802 -$3,670,471 $9.65 166
2025 Q2 42,035,725 $345,140,942 +$5,513,913 $8.21 159
2025 Q1 41,667,225 $297,962,085 -$1,501,158 $7.15 163
2024 Q4 42,074,510 $325,173,475 -$15,537,348 $7.73 175
2024 Q3 43,665,569 $458,056,433 -$8,522,130 $10.49 184
2024 Q2 43,782,930 $512,285,979 +$5,420,902 $11.70 180
2024 Q1 42,534,646 $895,831,731 +$95,824,018 $21.07 185
2023 Q4 38,123,027 $684,323,807 +$18,843,309 $17.95 167
2023 Q3 37,072,487 $610,280,035 -$2,249,035 $16.46 157
2023 Q2 37,122,782 $742,048,193 +$3,963,188 $19.99 165
2023 Q1 37,009,156 $699,776,275 +$18,824,498 $18.91 170
2022 Q4 35,702,552 $809,736,875 +$5,376,487 $22.68 180
2022 Q3 35,093,974 $927,284,018 -$30,479,732 $26.43 173
2022 Q2 36,159,183 $893,093,296 +$28,890,952 $24.70 157
2022 Q1 34,902,249 $1,157,712,999 -$21,017,474 $33.19 181
2021 Q4 35,507,306 $1,160,896,124 +$58,351,051 $32.70 168
2021 Q3 33,398,271 $1,400,353,918 -$3,046,167 $41.92 177
2021 Q2 33,460,640 $1,299,751,931 +$26,836,789 $38.85 168
2021 Q1 32,853,108 $1,120,584,466 +$187,839,315 $34.11 178
2020 Q4 27,329,284 $1,239,697,831 -$41,654,835 $45.36 182
2020 Q3 28,512,126 $785,403,793 -$29,743,448 $27.52 162
2020 Q2 29,376,827 $1,082,072,585 +$20,048,711 $36.83 174
2020 Q1 28,922,545 $936,893,202 -$29,109,226 $32.38 160
2019 Q4 29,584,479 $1,212,076,877 -$13,179,927 $40.97 178
2019 Q3 29,248,667 $1,041,238,768 -$21,895,746 $35.60 165
2019 Q2 29,447,574 $1,510,592,208 -$22,838,253 $51.37 184
2019 Q1 30,143,203 $1,727,382,727 +$15,646,108 $57.31 206
2018 Q4 29,941,433 $1,255,681,603 +$31,694,613 $41.95 178
2018 Q3 28,543,303 $2,154,975,590 +$194,166,110 $75.50 198
2018 Q2 26,028,733 $1,867,750,691 +$332,228,528 $71.75 174
2018 Q1 22,371,972 $667,791,727 +$29,287,426 $29.85 118
2017 Q4 21,584,761 $717,686,392 +$5,112,723 $33.25 106
2017 Q3 21,399,716 $704,035,906 -$14,361,368 $32.95 87
2017 Q2 22,655,785 $447,763,347 +$37,345,656 $19.75 86
2017 Q1 20,796,965 $401,380,019 +$94,928,884 $19.30 86
2016 Q4 18,300,126 $339,456,250 +$28,424,124 $18.55 77
2016 Q3 16,939,017 $237,123,842 +$3,104,010 $14.01 71
2016 Q2 17,911,156 $143,725,600 +$9,894,905 $8.00 67
2016 Q1 16,627,713 $179,564,518 +$4,021,922 $10.80 62
2015 Q4 15,040,714 $247,165,923 -$9,897,144 $16.60 65
2015 Q3 14,305,786 $310,215,000 +$310,214,985 $22.03 47